By Iain Gilbert
Date: Monday 01 Jul 2024
LONDON (ShareCast) - (Sharecast News) - Clinical infrastructure business Feedback has scored a contract with the Queen Victoria Hospital to provide its Bleepa Community Diagnostics Centre solution.
Feedback said on Monday that the contract was worth £495,000 for an initial 12-month term, with the ability to extend by another 12 months. It follows a procurement process launched by GVH back in November 2023.
The AIM-listed group stated the contract will see it provide digital infrastructure to help patient-specific pathways through the CDC, linking both primary and secondary care settings.
Chief executive Dr Tom Oakley said: "We are extremely pleased to announce that after two years of piloting our CDC solution with QVH we have been awarded a contract for the Bleepa platform. This contract will allow us to now expand the service offering to multiple GP practices and move beyond the breathlessness pathway to look at other specialty areas.
"This contract award is a compelling validation of our technology. QVH is an example that speaks to the rest of the NHS and is the pioneer of the symptom-based pathway on Bleepa, an approach which has demonstrated huge potential to cut wait times and improve care for patients. This contract will give others the confidence to progress with this care model and our platform, allowing us to now move forward to capture both the regional and national opportunity in front of us and ultimately to bring better, faster care to patients across the UK."
As of 1100 BST, Feedback shares had surged 15.65% to 85.0p.
Reporting by Iain Gilbert at Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 20.50p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 140.00p |
52 Week Low | 19.50p |
Volume | 0 |
Shares Issued | 13.33m |
Market Cap | £2.73m |
Beta | 0.43 |
RiskGrade | 267 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
You are here: research